Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.

Objective: The aim of this study was to evaluate the visual and structural outcomes of eyes that received ranibizumab as treatment for retinopathy of prematurity (ROP).

Methods: This was a retrospective case series of infants who received a 0.2 mg (0.